Basit öğe kaydını göster

dc.contributor.authorTavil, Betul
dc.contributor.authorAytac, Selin
dc.contributor.authorUnal, Sule
dc.contributor.authorKuskonmaz, Baris
dc.contributor.authorGumruk, Fatma
dc.contributor.authorCetin, Mualla
dc.date.accessioned2020-10-21T12:24:35Z
dc.date.available2020-10-21T12:24:35Z
dc.date.issued2016
dc.identifier.issn1536-3678
dc.identifier.urihttp://hdl.handle.net/11655/22996
dc.identifier.urihttps://doi.org/10.1097/MPH.0000000000000668
dc.description.abstractThe aim was to evaluate baseline demographic, clinical, and laboratory characteristics, treatment modalities, and outcome of children with idiopathic hypereosinophilic syndrome (HES) followed up in our center. Children who fulfilled the criteria of idiopathic HES followed up at Hacettepe University Faculty of Medicine, Pediatric Hematology Department between June 2004 and October 2013 were included in this study. Medical records of all children with idiopathic HES were reviewed to obtain regarding data. The mean age of 6 children with idiopathic HES was 52.8± 44.3 months (13 to 132 mo) at diagnosis. Among 6 children with idiopathic HES; 2 had pulmonary involvement; 1 had cardiac and pulmonary involvement and splenomegaly; 1 had cardiac involvement and hepatosplenomegaly; 1 had cardiac and central nervous system involvement; and 1 had skin involvement. The mean follow-up duration was 36.5± 31.4 months. Methyl prednisolone (MP) was used for the first-line therapy. Complete response was achieved with MP in 3 children. All steroid responsive children are alive; whereas 3 children who did not respond to MP had expired. In conclusion, cardiac and pulmonary involvement is the major causes of mortality in HES. Resistance to steroid therapy indicates poor prognosistr_TR
dc.language.isoentr_TR
dc.publisherLippincott Williams & Wilkinstr_TR
dc.relation.isversionof10.1097/MPH.0000000000000668tr_TR
dc.rightsinfo:eu-repo/semantics/openAccesstr_TR
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.subjectHypereosinophilic Syndrometr_TR
dc.titleHypereosinophilic Syndrome: Hacettepe Experience.tr_TR
dc.typeinfo:eu-repo/semantics/articletr_TR
dc.typeinfo:eu-repo/semantics/publishedVersion
dc.relation.journalJournal of Pediatric Hematology/Oncologytr_TR
dc.contributor.departmentÇocuk Sağlığı ve Hastalıklarıtr_TR
dc.identifier.volume38tr_TR
dc.identifier.issue7tr_TR
dc.identifier.startpage539tr_TR
dc.identifier.endpage543tr_TR
dc.description.indexWoStr_TR
dc.fundingYoktr_TR


Bu öğenin dosyaları:

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster

info:eu-repo/semantics/openAccess
Aksi belirtilmediği sürece bu öğenin lisansı: info:eu-repo/semantics/openAccess